Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 12, 2009
Wed, February 11, 2009 Candela Introduces the QuadraLase System Taking Fractional CO2 Therapy to the Next Level
WAYLAND, Mass.--([ BUSINESS WIRE ])--Candela Corporation (NASDAQ:CLZR)announced today the introduction of the new QuadraLASE™ laser. The QuadraLASE system combines the proven performance of a CO2 laser with an innovative scanning system giving practitioners a total solution for skin rejuvenation* and tightening** by treating wrinkles, uneven tone and texture, sun damage, acne scarring, the removal of skin tags, benign lesions and more. The Company will begin sales and marketing activities around the world with launch at the Annual Meeting of the American Academy of Dermatology, which takes place in San Francisco from March 6-10, 2009, and will commence shipments in March.
The QuadraLASE system utilizes the unique patent pending QuadraSCAN™ technology, which minimizes heat build-up in the skin, resulting in increased patient comfort. In addition, the system is engineered to fit the needs of every aesthetic practice offering:
- Value with no disposables – keeping long-term operating costs down.
- Choice of QS and QD handpieces providing true variable depth ablation.
- Elegant design and small footprint minimizing the need for space.
- Renowned Candela after-the-sale support.
"We are excited to be offering a unique solution for fractional ablation, one of the fastest growing segments of the aesthetic market," said Catherine A. Kniker, Senior Vice President of Marketing and Corporate Development. "We recognized the restrictions of fractional lasers and are now offering our QuadraLASE system to deliver a more desirable experience to patients and physicians. This advanced skin rejuvenation device will bring a whole new dimension to aesthetic medicine allowing practitioners to diversify treatment capabilities with a single device."
Kniker continued, "Candela has consistently developed gold standard products to treat the most popular applications, including leg and facial vein removal, skin rejuvenation and tightening, permanent hair reduction, tattoo and pigmented lesion removal and acne reduction. With the QuadraLASE system joining our suite of lasers, we now have the most comprehensive best-in-class solutions in the market."
Thomas E. Rohrer, M.D., SkinCare Physicians of Chestnut Hill (MA), who performed some of the studies, stated, "Based on my clinical experience with the QuadraLASE system, this device is very versatile, easy-to-use and comfortable for the patient, and it delivers excellent results."
About QuadraLASE: The new QuadraLASE fractional laser features proprietary QuadraSCAN technology, which reduces heat build-up in the skin, resulting in increased patient comfort. Candela QuadraLASE offers performance, versatility and value in a fractional CO2 laser. For more information please visit [ www.quadralase.com ] or call 800-733-8550 ext. 247.
* Skin rejuvenation through skin resurfacing.
** Skin tightening through wrinkle reduction.
QuadraLASE and QuadraSCAN are trademarks, and Candela is a registered trademark of Candela Corporation.
About CANDELA: Candela Corporation manufactures and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, Candela markets and services its products in 86 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 20 years ago, and currently has an installed base of over 13,500 systems worldwide. Visit Candela on the Web at [ http://www.candelalaser.com ].
Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela Corporation's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. These statements include declarations regarding our or our management's beliefs and current expectations. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of such terms or other comparable terminology. These forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could
cause the actual results to differ materially from those projected in these forward-looking statements. The risks and uncertainties that may affect forward-looking statements include, among others: the availability of, and our ability to successfully implement strategic and operational alternatives, the pendency of re-examinations of the ‘844 Patent and the ‘568 Patent before the PTO, our alleged infringement of the ‘844 Patent and the ‘568 Patent, the validity of the ‘844 Patent and the ‘568 Patent, our expected legal expenses, our exploration of strategic and operational alternatives, the expected recovery of our industry, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock, the cancellation or deferral of customer orders, the risk of a material adverse judgment or increased litigation-related expenses in pending litigation matters, dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.
